A laboratory can report strong test volume and still face a cash shortage when claims sit unresolved, denials repeat, and aging becomes accepted as normal. Effective lab accounts receivable management turns billed services into predictable cash, giving independent diagnostic and toxicology laboratories the control to invest in staff, technology, compliance, and growth.
For laboratory leaders, accounts receivable is not simply a collections function. It is a direct measure of how well the lab is managing documentation, coding, payer requirements, credentialing, claim submission, and follow-up. When any of those functions break down, the AR team inherits the problem after reimbursement is already at risk.
Why Lab Accounts Receivable Management Requires a Different Approach
Laboratory billing has its own reimbursement pressures. Medical necessity policies can vary by payer and test category. Ordering-provider information must be accurate. Coverage rules, modifiers, diagnosis-code support, prior authorization requirements, and timely filing deadlines all affect whether a claim is paid, denied, or delayed.
Urine toxicology laboratories face an added level of scrutiny. Payers frequently review ordering patterns, test utilization, definitive versus presumptive testing, and the clinical support behind billed services. A denial may be caused by a simple data issue, but it can also point to an intake, requisition, or ordering workflow that needs attention.
That distinction matters. A team focused only on collecting old balances may recover some revenue, but it will not necessarily stop new denials from entering the system. Strong AR management connects the back end of the revenue cycle to the front-end processes that determine claim quality.
Start With an AR Inventory You Can Trust
The first step is establishing a clear picture of the receivables portfolio. Total AR alone does not tell leadership where the true risk sits. The portfolio should be segmented by payer, age, denial reason, location or client source where applicable, test category, and responsible work queue.
Aging is useful, but it should not become the only management report. A growing 31-to-60-day bucket may signal a payer processing issue, a clearinghouse rejection pattern, or delays in posting electronic remittance advice. A high 91-plus-day balance can point to missed appeals, weak follow-up ownership, or unresolved credentialing problems.
Leaders should also separate collectible balances from balances that are unlikely to be recovered. This requires realistic financial classification and disciplined adjustment policies. Carrying unsupported old balances may make AR appear stronger on paper, but it obscures performance and weakens financial planning.
A practical AR review asks three questions: What is unpaid? Why is it unpaid? What action will move it? If reporting cannot answer all three, the laboratory lacks the visibility needed to manage cash effectively.
Measure More Than Days in AR
Days in AR remains a valuable indicator, especially when tracked over time. Still, it should be evaluated alongside clean claim rate, denial rate, first-pass payment rate, net collection rate, aged AR percentage, and recovery by payer category.
Benchmarks should be treated carefully. A reference laboratory with complex payer relationships will not look exactly like a small toxicology provider with a concentrated commercial payer mix. The more useful question is whether the lab’s own performance is improving, stable, or deteriorating – and whether leaders understand the reasons behind the trend.
Prioritize Accounts by Recoverability and Deadline
Not every unpaid claim deserves the same follow-up sequence. Teams that work AR strictly from oldest to newest often miss timely filing deadlines or spend too much time on low-value accounts with limited recovery potential.
A stronger approach prioritizes claims based on dollar value, payer behavior, filing and appeal deadlines, denial type, documentation needs, and probability of recovery. High-dollar claims nearing an appeal deadline should move quickly. Claims denied for missing information may be resolved with a focused correction. Repeated denials tied to a payer policy may require escalation and root-cause review before additional claims are submitted.
An effective work structure typically includes distinct queues for new denials, underpayments, no-response claims, credentialing-related denials, payer requests for records, and aged high-balance accounts. Clear ownership prevents claims from being touched repeatedly without meaningful progress.
Follow-up notes should document the payer contact, reference number, action taken, expected response date, and next required step. That level of documentation protects continuity when work moves between team members and makes management oversight far more effective.
Prevent Denials Before They Reach AR
The most profitable denial is the one the lab never receives. Denial prevention begins before testing and continues through charge capture and claim submission.
For diagnostic and toxicology laboratories, front-end controls often include complete patient demographics, active insurance verification, accurate ordering-provider details, valid diagnosis information, signed and legible requisitions when required, and processes for obtaining missing documentation before a claim is filed. The right controls depend on the lab’s services, payer mix, and state requirements, but the principle is consistent: do not send claims that staff already know lack essential support.
Claim edits should reflect current payer requirements rather than generic billing rules. An edit that catches an invalid member ID is useful. An edit that identifies a diagnosis-code mismatch for a specific test and payer can prevent a more costly denial cycle.
Denial patterns should be reviewed at least monthly with billing, operations, and laboratory leadership. If one denial reason is increasing, the conversation should move beyond, “How do we appeal this?” to, “What process allowed this claim to leave the lab?” This is where AR becomes an operational improvement tool rather than a back-office report.
Manage Payer Performance, Not Just Payer Balances
Payers do not behave the same way. One may process clean claims quickly but frequently underpay a particular service. Another may issue broad medical necessity denials that require records and persistent appeal work. A third may be slow to load a newly credentialed provider or laboratory location, creating avoidable nonparticipating payment issues.
Payer-level reporting gives laboratory leaders the evidence to address these differences. Track payment turnaround, denial rate, underpayment frequency, appeal overturn rate, and recurring denial codes for each meaningful payer relationship. This information can guide contract discussions, escalation strategies, staffing decisions, and credentialing follow-up.
Underpayments deserve special attention. A claim that pays is not automatically a correct payment. Contractual reimbursement terms, fee schedules, multiple-procedure logic, and payer edits should be checked against expected reimbursement. Small variances can become material revenue loss when they recur across a high-volume test menu.
There is a trade-off. Building detailed expected-payment models requires effort and dependable contract data. For some smaller labs, beginning with the largest payers and highest-volume services delivers the best return. The objective is not to audit every dollar immediately. It is to identify where payment variance creates the greatest financial exposure.
Build a Consistent AR Operating Cadence
Accounts receivable improves when it has a regular management rhythm, not when it becomes an emergency project at month-end. Leadership should review key trends weekly, while the AR team works daily from defined priorities and documented escalation paths.
A productive cadence includes four connected activities:
- Daily review of electronic rejections, new denials, and claims approaching filing deadlines.
- Weekly review of payer-specific barriers, high-dollar accounts, and unresolved documentation requests.
- Monthly analysis of aging movement, denial trends, underpayments, and recovery performance.
- Quarterly review of payer strategy, credentialing status, workflow gaps, and technology needs.
This cadence creates accountability without turning every issue into a leadership meeting. Staff have clear direction for routine work, while systemic risks reach decision-makers before they affect several months of revenue.
Know When Outside Expertise Adds Value
Some laboratories have capable internal billing staff but lack the specialized capacity to manage complex payer disputes, monitor contract underpayments, or rebuild denial-prone workflows. Others are growing faster than their revenue cycle infrastructure can support. In either case, outsourcing or augmenting AR operations can be a strategic decision rather than a response to failure.
The right partner should do more than make collection calls. Look for healthcare-specific experience, familiarity with laboratory reimbursement, transparent reporting, documented escalation processes, and the ability to identify upstream causes of AR growth. The best support model fits the lab’s existing team and creates knowledge transfer instead of simply moving problems outside the organization.
Revenue Management Corporation approaches laboratory revenue performance as part of the broader business picture. AR follow-up, payer reimbursement, credentialing, billing workflow, and operational oversight should work together to support sustainable growth.
Healthy AR is not defined by a single aging percentage or a short-term reduction in old balances. It is defined by a laboratory’s ability to see problems early, act on the right accounts, prevent repeat denials, and make smart long-term decisions with confidence. When that discipline is in place, receivables become a source of financial control rather than a monthly source of uncertainty.
Recent Comments